comparemela.com

Page 5 - Giuseppe Ciaramella News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Beam Therapeutics (BEAM) Presents Preclinical Data Highlighting Utility of BEAM-302

Beam Therapeutics (BEAM) Presents Preclinical Data Highlighting Utility of BEAM-302
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Beam Therapeutics (NASDAQ:BEAM) Receives Overweight Rating from Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their overweight rating on shares of Beam Therapeutics (NASDAQ:BEAM – Free Report) in a report published on Tuesday morning, Benzinga reports. They currently have a $56.00 price objective on the stock. Other equities research analysts have also issued reports about the company. Wedbush restated an outperform rating and set a $79.00 price […]

Pearl River Capital LLC Has $449,000 Stock Holdings in Beam Therapeutics Inc (NASDAQ:BEAM)

Pearl River Capital LLC raised its holdings in shares of Beam Therapeutics Inc. (NASDAQ:BEAM – Free Report) by 37.9% in the 1st quarter, HoldingsChannel reports. The firm owned 14,676 shares of the company’s stock after buying an additional 4,036 shares during the period. Pearl River Capital LLC’s holdings in Beam Therapeutics were worth $449,000 as […]

Cantor Fitzgerald Reaffirms Overweight Rating for Beam Therapeutics (NASDAQ:BEAM)

Cantor Fitzgerald Reaffirms Overweight Rating for Beam Therapeutics (NASDAQ:BEAM)
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Beam Therapeutics (NASDAQ:BEAM) Earns Overweight Rating from Cantor Fitzgerald

Beam Therapeutics (NASDAQ:BEAM – Get Free Report)‘s stock had its “overweight” rating reissued by analysts at Cantor Fitzgerald in a research note issued to investors on Tuesday, Benzinga reports. They currently have a $56.00 price target on the stock. Cantor Fitzgerald’s price target points to a potential upside of 136.39% from the company’s previous close. […]

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.